Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
See how to make money instead of spending it on Black Friday with this offer (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Musk plans to relaunch Twitter premium service, again
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
See how to make money instead of spending it on Black Friday with this offer (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Musk plans to relaunch Twitter premium service, again
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
See how to make money instead of spending it on Black Friday with this offer (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Musk plans to relaunch Twitter premium service, again
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
See how to make money instead of spending it on Black Friday with this offer (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Musk plans to relaunch Twitter premium service, again
NYSE:BIO

Bio-Rad Laboratories - BIO Stock Forecast, Price & News

$404.06
+0.12 (+0.03%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$400.77
$406.54
50-Day Range
$351.71
$456.01
52-Week Range
$344.63
$771.69
Volume
54,007 shs
Average Volume
212,605 shs
Market Capitalization
$12.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$680.00

Bio-Rad Laboratories MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
68.3% Upside
$680.00 Price Target
Short Interest
Healthy
1.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.54
Upright™ Environmental Score
News Sentiment
0.57mentions of Bio-Rad Laboratories in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
4.66%
From $14.38 to $15.05 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

144th out of 1,044 stocks

Analytical Instruments Industry

4th out of 28 stocks

BIO stock logo

About Bio-Rad Laboratories (NYSE:BIO) Stock

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BIO Stock News Headlines

Bio-Rad Reports Third-Quarter 2022 Financial Results
Bio-Rad Shares Fall After Report of Qiagen Talks
Bio-Rad Labs and Qiagen in Combination Talks - WSJ
Bio-Rad Laboratories in Talks to Combine With Qiagen
Diagnostics firm Bio-Rad in talks to merge with Qiagen - WSJ
See More Headlines
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BIO Company Calendar

Last Earnings
10/27/2022
Today
11/26/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/09/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
CUSIP
09057220
Employees
7,900
Year Founded
1952

Price Target and Rating

Average Stock Price Forecast
$680.00
High Stock Price Forecast
$700.00
Low Stock Price Forecast
$640.00
Forecasted Upside/Downside
+68.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$4.25 billion
Net Margins
-215.16%
Pretax Margin
-279.57%

Debt

Sales & Book Value

Annual Sales
$2.92 billion
Cash Flow
$15.81 per share
Book Value
$283.45 per share

Miscellaneous

Free Float
21,652,000
Market Cap
$12.05 billion
Optionable
Optionable
Beta
0.92

Social Links


Key Executives

  • Mr. Norman D. Schwartz (Age 72)
    Chairman, CEO & Pres
    Comp: $3.15M
  • Mr. Ilan  DaskalMr. Ilan Daskal (Age 56)
    Exec. VP & CFO
    Comp: $1.18M
  • Dr. Andrew J. Last Ph.D. (Age 62)
    Exec. VP & COO
    Comp: $1.54M
  • Mr. Michael  CrowleyMr. Michael Crowley (Age 60)
    Exec. VP of Global Commercial Operations
    Comp: $974.94k
  • Ms. Dara Grantham Wright (Age 46)
    Exec. VP & Pres of Clinical Diagnostics Group
    Comp: $1.06M
  • Mr. Ajit  RamalingamMr. Ajit Ramalingam (Age 49)
    Sr. VP & Chief Accounting Officer
  • Mr. Yong Chung
    VP of Investor Relations
  • Mr. Timothy S. ErnstMr. Timothy S. Ernst (Age 62)
    Exec. VP, Gen. Counsel & Sec.
  • Colleen Corey
    Sr. VP of Global HR
  • Lee Boyd
    Sr. VP of Global Commercial Operations - Asia Pacific













BIO Stock - Frequently Asked Questions

Should I buy or sell Bio-Rad Laboratories stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIO shares.
View BIO analyst ratings
or view top-rated stocks.

What is Bio-Rad Laboratories' stock price forecast for 2023?

3 equities research analysts have issued 1 year price targets for Bio-Rad Laboratories' stock. Their BIO share price forecasts range from $640.00 to $700.00. On average, they anticipate the company's stock price to reach $680.00 in the next twelve months. This suggests a possible upside of 68.3% from the stock's current price.
View analysts price targets for BIO
or view top-rated stocks among Wall Street analysts.

How have BIO shares performed in 2022?

Bio-Rad Laboratories' stock was trading at $755.57 at the start of the year. Since then, BIO stock has decreased by 46.5% and is now trading at $404.06.
View the best growth stocks for 2022 here
.

When is Bio-Rad Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our BIO earnings forecast
.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) announced its quarterly earnings data on Thursday, October, 27th. The medical research company reported $2.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.01. The medical research company had revenue of $680.10 million for the quarter, compared to analyst estimates of $685.50 million. Bio-Rad Laboratories had a positive trailing twelve-month return on equity of 4.13% and a negative net margin of 215.16%. The company's quarterly revenue was down 9.0% on a year-over-year basis. During the same period in the previous year, the company earned $3.71 EPS.
Read the conference call transcript
.

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories updated its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.95 billion-$2.95 billion, compared to the consensus revenue estimate of $2.84 billion.

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.88%), BlackRock Inc. (5.32%), Veritas Asset Management LLP (3.34%), State Street Corp (3.21%), Brown Advisory Inc. (2.60%) and Alliancebernstein L.P. (1.79%). Insiders that own company stock include Ajit Ramalingam, Annette Tumolo, Giovanni Magni, Ilan Daskal, Michael Crowley, Ronald W Hutton and Timothy S Ernst.
View institutional ownership trends
.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $404.06.

How much money does Bio-Rad Laboratories make?

Bio-Rad Laboratories (NYSE:BIO) has a market capitalization of $12.05 billion and generates $2.92 billion in revenue each year. The medical research company earns $4.25 billion in net income (profit) each year or ($201.80) on an earnings per share basis.

How many employees does Bio-Rad Laboratories have?

The company employs 7,900 workers across the globe.

Does Bio-Rad Laboratories have any subsidiaries?
The following companies are subsidiares of Bio-Rad Laboratories: (f/k/a Bio-Rad Laboratories (Israel) Inc.), BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad Finland Oy (f/k/a DiaMed Fennica Oy), Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Rishon) Inc., Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Pasteur, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Biotest - Businesses, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, Ciphergen Biosystems - ProteinChip Systems Business, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed France SA, DiaMed GmbH, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., Dropworks Inc., GnuBIO Inc., Helix Diagnostics, IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, Propel Labs - Cell Sorting System Division, QuantaLife, Quantase Ltd., Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd..
Read More
How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The official website for the company is www.bio-rad.com. The medical research company can be reached via phone at (510) 724-7000, via email at investor_relations@bio-rad.com, or via fax at 510-741-5817.

This page (NYSE:BIO) was last updated on 11/26/2022 by MarketBeat.com Staff